A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Model scores of the 29,894 trials active now.

Model score 3% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 5% of the time (4,470 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-06-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: subjects withmatchedtransplantationfunctionallowed
  Phrases that lowered it: participantshealthysingle dosescreeningmedical history
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Phase: 1 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 0% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 9 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment NCT01727128 · started 2011 · scored riskier than 2% of active trials completed
• A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function NCT05835180 · started 2023 · scored riskier than 5% of active trials completed
• Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function NCT04454424 · started 2020 · scored riskier than 11% of active trials completed
• Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function NCT05765344 · started 2023 · scored riskier than 5% of active trials completed
• A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment NCT05624710 · started 2022 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.